Medinice S.A (ICE) Fair Value & Analysis
Healthcare · PL · Market cap 820M PLN
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −0.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 7.73 PLN – 90.70 PLN · fair‑value band 32.02 PLN – 53.37 PLN · the 72.00 PLN price screens above the 42.70 PLN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medinice S.A (ICE) currently trades at 72.00 PLN, while our model-based Fair Value estimate is 42.70 PLN — implying the stock looks roughly 40.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 19.0K PLN. Revenue declined 61.2% year over year. It earns a return on equity of -8.0%. The balance sheet holds a net cash position of 8.8M PLN. Fundamentals as of Jun 24, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium; and AtriClamp, a clip designed to close the left atrial appendage to minimize the risk of stroke in patients with atrial fibrillation. It also provides MiniMax, an ablation-mapping catheter used for detecting intracardiac electrophysiological signals, creating a 3D map of the heart, and performing intracardiac irrigated RF ablation to treat arrhythmias caused by abnormalities in the heart's conduction system; and EP Bioptom, an electrode for endomyocardial biopsy using 3D mapping enabling simultaneous biopsy and creation of a three-dimensi…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medinice S.A reported revenue of 0 PLN in FY2025 versus 288K PLN in FY2021. Reported net income was −6.7M PLN in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medinice S.A (ICE) undervalued?
What is the fair value of ICE?
What is the quality score of ICE?
What is the revenue of Medinice S.A (ICE)?
What is the net profit margin of ICE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.